We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Editor's Correspondence |

Potential Safety Signals and Their Significance

Emily Jane Woo, MD, MPH
Arch Intern Med. 2012;172(9):747-748. doi:10.1001/archinternmed.2012.833.
Text Size: A A A
Published online


As Powers and Cook1 and Dal Pan and Temple2 have stated, biweekly screening of disproportionality within the Adverse Event Reporting System (AERS) is a valuable tool for identifying potential safety signals. However, it is only 1 component of routine surveillance at the US Food and Drug Administration (FDA). In accordance with the Food and Drug Administration Amendments Act of 2007 (FDAAA), the FDA performs formal safety reviews at specified time points. Twelve months after the licensure of pediatric drugs and biological products, FDA physicians review the relevant data, summarize their findings, and present the results to an independent advisory committee, who will assess the reviews and make recommendations for action.3 Postmarketing evaluations are also performed 18 months after approval of a drug or biological product or use of the product by 10 000 individuals (including both adults and children), whichever occurs later. The evaluations are performed to determine whether there are any new safety concerns that were not previously identified during product development. Safety evaluation summaries are posted on the FDA's website.4



Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





May 14, 2012
Gerald J. Dal Pan, MD, MHS
Arch Intern Med. 2012;172(9):747-748. doi:10.1001/archinternmed.2012.1035.
May 14, 2012
G. Elliott Cook, PharmD, BCPS; Abbey Powers, PharmD
Arch Intern Med. 2012;172(9):747-748. doi:10.1001/archinternmed.2012.1297.
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles